|
iSquad introduction video
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
90 days in the life of an iSL-part 1
Content Declaration
Keep for 3 Years
|
|
90 days in the life of an iSL-part 2
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
This mini video series (4) looks at some of the principles of agility, like what is the right mindset for an agile transformation, how to work agile, how to enable agile teams and how to co-create…
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
This mini video series (4) looks at some of the principles of agility, like what is the right mindset for an agile transformation, how to work agile, how to enable agile teams and how to co-create…
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
This mini video series (4) looks at some of the principles of agility, like what is the right mindset for an agile transformation, how to work agile, how to enable agile teams and how to co-create…
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
This mini video series (4) looks at some of the principles of agility, like what is the right mindset for an agile transformation, how to work agile, how to enable agile teams and how to co-create…
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
Learning through conversations with Virtual Humans https://sites.google.com/roche.com/bet/capability-home/vr-learning-experience
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
Dr J.Gschwend presented the results from the IMvigor010 ctDNA analysis at the Game changing session at EAU 2021. IMvigor010, a Phase III study, evaluated adjuvant treatment with atezolizumab compared…
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
Dr J.Gschwend presented the results from the IMvigor010 ctDNA analysis at the Game changing session at EAU 2021. IMvigor010, a Phase III study, evaluated adjuvant treatment with atezolizumab compared…
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
PI3K/AKT
pathway biomarkers analysis from the Phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic
castration-resistant prostate cancer
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
CONTACT-03
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
CONTACT-02 VIDEO
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
CheckMate 9KD arm B final analysis
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
A phase 3 trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer
Content Declaration
Keep for 3 Years Language (In English)
English
|
|
HIF2a + cabozantinib phase II VIDEO
Content Declaration
Keep for 3 Years Language (In English)
English
|